Biofrontera Inc. Reports Third Quarter 2022 Financial Results and Provides a Business UpdateGlobeNewsWire • 11/14/22
Biofrontera Inc. to Report Third Quarter Financial Results on November 14, 2022GlobeNewsWire • 11/10/22
Biofrontera Inc. Fully Exercises Recently Acquired Options to Purchase Shares of Biofrontera AGGlobeNewsWire • 11/08/22
Biofrontera Inc. Enters into Agreements to Purchase Options of Biofrontera AGGlobeNewsWire • 10/31/22
Biofrontera Inc. to Present at the LD Micro Main Event XV Investor ConferenceGlobeNewsWire • 10/20/22
BIOFRONTERA INC. TO PARTICIPATE IN RENMARK'S VIRTUAL NON-DEAL ROADSHOW SERIES ON FRIDAY OCTOBER 14, AND TUESDAY OCTOBER 18, 2022GlobeNewsWire • 10/12/22
Biofrontera Inc. Announces Preliminary Product Revenues for the Third Quarter of 2022GlobeNewsWire • 10/05/22
Biofrontera Inc. to Present at the Roth Inaugural Healthcare Opportunities ConferenceGlobeNewsWire • 09/29/22
Biofrontera Inc.'s Marketing Campaign and Website for Ameluz Won 2022 PM360 Trailblazer AwardsGlobeNewsWire • 09/26/22
Biofrontera Inc. Announces Notice of Allowance for Nanoemulsion Composition-of-Matter U.S. PatentGlobeNewsWire • 09/06/22
Biofrontera Inc.'s Leslie Hopkins Named PM360 Trailblazer 2022 Brand Champion for DermatologyGlobeNewsWire • 08/18/22
Biofrontera Inc.'s (BFRI) CEO Erica Monaco on Q2 2022 Results - Earnings Call TranscriptSeeking Alpha • 08/12/22
Biofrontera Inc. Reports Second Quarter 2022 Financial Results and Provides a Business UpdateGlobeNewsWire • 08/12/22
Biofrontera Inc. Announces Patent in Australia for Novel Illumination Protocols Granted to Biofrontera Bioscience GmbHGlobeNewsWire • 08/01/22
Biofrontera Inc. Announces Exercise of Existing Warrants and Issuance of Warrants in Private PlacementGlobeNewsWire • 07/27/22
Biofrontera, Inc. Recognized for Rapid Sales Growth, Innovative Therapies and Marketing ExcellenceGlobeNewsWire • 06/09/22
Biofrontera Inc. to Participate in The Benchmark Healthcare House Call Virtual 1x1 ConferenceGlobeNewsWire • 05/31/22
New Data and Forecasts for the U.S. Skin Cancer Market Strongly Support the Commercial Opportunity for Biofrontera's Ameluz®GlobeNewsWire • 05/24/22